QAS Ticagrelor DTP

Vocabulary flashcards detailing the drug class, pharmacology, indications, contraindications, precautions, presentations, and pharmacokinetics of Ticagrelor according to clinical protocols.

Drug Class

Antiplatelet

Pharmacology

A reversibly binding, direct-acting adenosine diphosphate (ADP) receptor antagonist that inhibits platelet activation and aggregation.

Metabolism

Hepatic

Indications

Patients with STEMI or STEMI equivalent (as defined by the relevant QAS CPP) who have been accepted for pPCI (as an adjunct medication to aspirin and heparin) AND the receiving interventional cardiologist is requesting ticagrelor administration.

Contraindications

Refer to pre hospital cardiac reperfusion checklist

1. Allergy and/or adverse drug reaction

2. Patients less than 18 years old

3. MRS equal to or greater than 4

4. Ischaemic chest pain greater than 12 hours

5. History of terminal illness, or under care of a palliative care service

6. Symptoms suggestive of an acute aortic dissection

7. Patients currently taking Ticagrelor or Clopidogrel

8. Prior intracranial haemorrhage

9. Active bleeding (excluding menstruation)

Precautions

1. Concurrent medication known to induce bradycardia (e.g. B-blocker, calcium channel blocker, digoxin)

2. Symptomatic bradycardia (HR less than 60)

3. Hepatic impairment.

Side Effects

Haemorrhage.

Presentation

Tablet, 90mg, Ticagrelor

Orally Disintegrating Tablet (ODT), 90mg ticagrelor

Onset

Roughly 30 minutes

Duration

7 days (antiplatelet)

Half-life

7 hours

Adult Doses

PO: 180mg